Memo Therapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 17
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $15.2M
Latest Deal Amount
  • Investors
  • 10

Memo Therapeutics General Information

Description

Developer of antibody discovery and immune repertoire analysis platform intended to help cure diseases. The company's platform creates a recombinant in vitro copy of an individual's B cell/antibody repertoire, which libraries represent the individual's immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies that leads to entirely new possibilities in immune repertoire analysis and antibody discovery, enabling physicians to progress towards molecular cloning, biobanking and expression-screening of all the antibodies in an organism.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Discovery Tools (Healthcare)
Primary Office
  • Wagistrasse 27
  • 8952 Schlieren
  • Switzerland
+41 044 000 00 00

Memo Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Memo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 06-Nov-2020 $15.2M 000.00 000.00 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series A2) 17-Dec-2018 00.000 00.000 000.00 Completed Pre-Clinical Trials
2. Grant 10-Jul-2017 $2.35M Completed Generating Revenue
1. Early Stage VC (Series A) 01-Apr-2015 $2.35M $2.35M 00.000 Completed Generating Revenue
To view Memo Therapeutics’s complete valuation and funding history, request access »

Memo Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000 00.000000 000.00 000.00 00 000.00 00.000
Series B 000,000 00.000000 000.00 000.00 00 000.00 00.000
Series A2 00,000 00.000000 000.00 000.00 00 000.00 00.000
Series A2 31,795 $1.096239 $69.37 $69.37 1x $69.37 6.66%
Series A 84,958 $1.096239 $29.68 $29.68 1x $29.68 17.8%
To view Memo Therapeutics’s complete cap table history, request access »

Memo Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of antibody discovery and immune repertoire analysis platform intended to help cure diseases. The company's pl
Drug Discovery
Schlieren, Switzerland
17 As of 2021
000.00
00.00 0000-00-00
00000000000 000.00

00000

consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat n
0000 000000000
Cambridge, United Kingdom
000 As of 0000
00000
0.000 0000-00-00
000000&0 00000

000000

do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
0000000000000
Ghent, Belgium
000 As of 0000
00000
0.000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Memo Therapeutics Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kymab Formerly VC-backed Cambridge, United Kingdom 000 00000 000000&0 00000
000000 Formerly VC-backed Ghent, Belgium 000 00000 000000&0 00000
0000 000000000000 Formerly VC-backed Utrecht, Netherlands 00 00000 00000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.000 000000000 00.000
You’re viewing 5 of 21 competitors. Get the full list »

Memo Therapeutics Patents

Memo Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2017510292-A Method for recovering two or more genes or gene products encoding immunoreceptors Pending 14-Feb-2014 0000000000 0
JP-2020054355-A Method for recovering two or more genes or gene products encoding immunoreceptor Pending 14-Feb-2014 00000000000
GB-201402591-D0 Method for recovering two or more genes, or gene products, encoding an immunoreceptor Ceased 14-Feb-2014 0000000000
EP-3105248-A1 Method for recovering two or more genes, or gene products, encoding an immunoreceptor Granted 14-Feb-2014 00000000000
ES-2848032-T3 Method of retrieving two or more genes, or gene products, that code for an immunoreceptor Active 14-Feb-2014 C12Q1/6806

Memo Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Christoph Esslinger Ph.D Co-Founder, Chief Scientific Officer & Board Member
Karsten Fischer Ph.D Chief Executive Officer
Dragan Gabulovski Chairman of the Board & Executive of Business Development and Strategy
George Badita Chief Medical Officer
Elias Papatheodorou Independent Chairman
You’re viewing 5 of 6 executive team members. Get the full list »

Memo Therapeutics Board Members (9)

Name Representing Role Since
Christoph Esslinger Ph.D Memo Therapeutics Co-Founder, Chief Scientific Officer & Board Member 000 0000
Dragan Gabulovski Memo Therapeutics Chairman of the Board & Executive of Business Development and Strategy 000 0000
Elias Papatheodorou Self Independent Chairman 000 0000
Nadine Geiser Ph.D Redalpine Venture Partners Board Member 000 0000
Peter Burckhardt Ph.D Eva Capital Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Memo Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Memo Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BERNINA BioInvest Venture Capital Minority 000 0000 000000 0
Jaquet Partners Family Office Minority 000 0000 000000 0
Swisscanto Private Equity Asset Manager Minority 000 0000 000000 0
Schroders Capital Asset Manager Minority 000 0000 000000 0
Verve Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »